Relationship between negative symptoms and plasma levels of insulin-like growth factor 1 in first-episode schizophrenia and bipolar disorder patients

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 44, Issue , 2013, Pages 29-33

  Palomino, Aitor ^a   González Pinto, Ana ^a   Martinez Cengotitabengoa, Mónica ^a   Ruiz de Azua, Sonia ^a   Alberich, Susana ^a   Mosquera, Fernando ^a   Matute, Carlos ^a  

^a UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

Author keywords

Bipolar disorder; First psychotic episode; IGF 1; Negative symptoms; Schizophrenia

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; MOOD STABILIZER; NEUROLEPTIC AGENT; SOMATOMEDIN C;

ADULT; AGE; ARTICLE; BIPOLAR DISORDER; CLINICAL ARTICLE; CLINICAL FEATURE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; EDUCATIONAL STATUS; FEMALE; FIRST EPISODE SCHIZOPHRENIA; FOLLOW UP; GENDER; GLOBAL ASSESSMENT OF FUNCTIONING; HAMILTON SCALE; HUMAN; MALE; NEGATIVE SYNDROME; POSITIVE AND NEGATIVE SYNDROME SCALE; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; SCHIZOPHRENIA; SOMATOMEDIN C BLOOD LEVEL; SPAIN; STATISTICAL SIGNIFICANCE; YOUNG MANIA RATING SCALE;

ADULT; ANALYSIS OF VARIANCE; BIPOLAR DISORDER; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MALE; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; STATISTICS, NONPARAMETRIC; YOUNG ADULT;

EID: 84873889686     PISSN: 02785846     EISSN: 18784216     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2013.01.008     Document Type: Article

References (26)

1. Aleman A., Torres-Aleman I. Circulating insulin-like growth factor I and cognitive function: neuromodulation throughout the lifespan. Prog Neurobiol 2009, 89:256-265.
2. Altar C.A., Hunt R.A., Jurata L.W., Webster M.J., Derby E., Gallagher P., et al. Insulin, IGF-1, and muscarinic agonists modulate schizophrenia-associated genes in human neuroblastoma cells. Biol Psychiatry 2008, 64:1077-1087.
3. Chen M.J., Russo-Neustadt A.A. Running exercise- and antidepressant-induced increases in growth and survival-associated signaling molecules are IGF-dependent. Growth Factors 2007, 25:118-131.
4. Duman C.H., Schlesinger L., Terwilliger R., Russell D.S., Newton S.S., Duman R.S. Peripheral insulin-like growth factor-I produces antidepressant-like behavior and contributes to the effect of exercise. Behav Brain Res 2009, 198:366-371.
5. Endicott J., Spitzer R.L., Fleiss J.L., Cohen J. The global assessment scale. A procedure for measuring overall severity of psychiatric disturbance. Arch Gen Psychiatry 1976, 33:766-771.
6. Galvin J., Eyermann C., Colognato H. Dystroglycan modulates the ability of insulin-like growth factor-1 to promote oligodendrocyte differentiation. J Neurosci Res 2010, 88:3295-3307.
7. Gluckman P.D., Guan J., Williams C., Scheepens A., Zhang R., Bennet L., et al. Asphyxial brain injury-the role of the IGF system. Mol Cell Endocrinol 1998, 140:95-99.
8. Gunnell D., Holly J.M. Insulin-like growth factors, insulin resistance and schizophrenia. Br J Psychiatry 2004, 185:353-354.
9. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960, 23:56-62.
10. Holt R.I., Simpson H.L., Sonksen P.H. The role of the growth hormone-insulin-like growth factor axis in glucose homeostasis. Diabet Med 2003, 20:3-15.
11. Insel T.R. Rethinking schizophrenia. Nature 2010, 468:187-193.
12. Kay S.R., Fiszbein A., Opler L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987, 13:261-276.
13. Khalil R.B. Recombinant human IGF-1 for patients with schizophrenia. Med Hypotheses 2011, 77:427-429.
14. Le R.D. The insulin-like growth factor system. Exp Diabesity Res 2003, 4:205-212.
15. Lin E.J., Lee N.J., Slack K., Karl T., Duffy L., O'brien E., et al. Distinct endocrine effects of chronic haloperidol or risperidone administration in male rats. Neuropharmacology 2006, 51:1129-1136.
16. Melkersson K.I., Hulting A.L., Brismar K.E. Different influences of classical antipsychotics and clozapine on glucose-insulin homeostasis in patients with schizophrenia or related psychoses. J Clin Psychiatry 1999, 60:783-791.
17. Melkersson K.I., Hulting A.L., Rane A.J. Dose requirement and prolactin elevation of antipsychotics in male and female patients with schizophrenia or related psychoses. Br J Clin Pharmacol 2001, 51:317-324.
18. Niblock M.M., Brunso-Bechtold J.K., Riddle D.R. Insulin-like growth factor I stimulates dendritic growth in primary somatosensory cortex. J Neurosci 2000, 20:4165-4176.
19. Perrin M.A., Chen H., Sandberg D.E., Malaspina D., Brown A.S. Growth trajectory during early life and risk of adult schizophrenia. Br J Psychiatry 2007, 191:512-520.
20. Ryan M.C., Thakore J.H. Physical consequences of schizophrenia and its treatment: the metabolic syndrome. Life Sci 2002, 71:239-257.
21. Ryan M.C., Collins P., Thakore J.H. Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia. Am J Psychiatry 2003, 160:284-289.
22. Saleh N., Moutereau S., Azulay J.P., Verny C., Simonin C., Tranchant C., et al. High insulin like growth factor I is associated with cognitive decline in Huntington disease. Neurology 2010, 75:57-63.
23. Venkatasubramanian G., Chittiprol S., Neelakantachar N., Naveen M.N., Thirthall J., Gangadhar B.N., et al. Insulin and insulin-like growth factor-1 abnormalities in antipsychotic-naive schizophrenia. Am J Psychiatry 2007, 164:1557-1560.
24. Venkatasubramanian G., Chittiprol S., Neelakantachar N., Shetty T., Gangadhar B.N. Effect of antipsychotic treatment on insulin-like growth factor-1 and cortisol in schizophrenia: a longitudinal study. Schizophr Res 2010, 119:131-137.
25. Walhbeck K., Osmond C., Forsen T., Barker D.J. Associations between childhood living circumstances and schizophrenia: a population-based cohort study. Acta Psychiatr Scand 2001, 104:356-360.
26. Young R.C., Biggs J.T., Ziegler V.E., Meyer D.A. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry 1978, 133:429-435.